Publication at Faculty of Medicine in Pilsen |
2013
Abstract
Our case report shows a case of 61 - year old patient with NSCLC (non-small cell lung cancer) with two „driving mutations“ – EGFR and KRAS, which are relatively rarely incident according to literature. Our investigation demonstates that EGFR-TKI (erlotinib in our case) can be efficiant therapeutical modality in these types of tumors.
Subsequently, in the discussion we concentrate on possible use of KRAS status as a predicitve or prognostic marker in NSCLC.